Effect of early cardiac rehabilitation on prognosis in patients with heart failure following acute myocardial infarction

He Cai¹, Pengyu Cao¹*, Wenqian Zhou¹, Wanqing Sun², Xinying Zhang¹, Rongyu Li¹, Wangshu Shao¹, Lin Wang¹, Lin Zou¹ and Yang Zheng¹

Abstract

Objective: The purpose of this retrospective study is to evaluate the effectiveness of early cardiac rehabilitation on patients with heart failure following acute myocardial infarction.

Methods: Two hundred and thirty-two patients who developed heart failure following acute myocardial infarction were enrolled in this study. Patients were divided into heart failure with reduced ejection fraction group (n = 54) and heart failure with mid-range ejection fraction group (n = 178). Seventy-eight patients who accepted a two-week cardiac rehabilitation were further divided into two subgroups based on major adverse cardiovascular events. Key cardio-pulmonary exercise testing indicators that may affect the prognosis were identified among the cardiac rehabilitation patients.

Results: Early cardiac rehabilitation significantly reduced cardiac death and re-hospitalization in patients. There was more incidence of diabetes, hyperkalemia and low PETCO₂ in the cardiac rehabilitation group who developed re-hospitalization. Low PETCO₂ at anaerobic threshold (≤33.5 mmHg) was an independent risk factor for re-hospitalization.

Conclusions: Early cardiac rehabilitation reduced major cardiac events in patients with heart failure following acute myocardial infarction. The lower PETCO₂ at anaerobic threshold is an independent risk factor for re-hospitalization, and could be used as a evaluating hallmark for early cardiac rehabilitation.

Keywords: Cardiac rehabilitation, Cardio-respiratory fitness, Cardio-pulmonary exercise, Heart failure, Exercise training, Electrical stimulation, Cardiovascular events

Introduction

Congestive heart failure (CHF) is a major cause of mortality and morbidity and the end pathophysiological condition of many cardiovascular diseases [1]. One of the leading causes of CHF is myocardial infarction. Percutaneous coronary intervention (PCI) significantly decreased the mortality in patients with acute myocardial infarction (AMI) [2]. However, CHF continues to develop in some patients before or soon after PCI.

Exercise intolerance, represented as decreased capacity to perform physical activities with symptoms of severe fatigue and/or dyspnea, is a characteristic of CHF and associated with increased mortality and reduced quality of life (QoL) [3]. The pathophysiological mechanisms of exercise intolerance in CHF are multifactorial, involving impaired cardiac and pulmonary reserve as well as decreased respiratory and peripheral skeletal muscle function [4]. In addition to conventional treatment, research have shown that secondary prevention
through comprehensive cardiac rehabilitation (CR) were the most cost-effective intervention to ensure favorable outcomes, to improve exercise capacity and QoL, and to minimize re-hospitalizations in patients with CHF [5–7]. Passive or active exercise of CR is beneficial for patients with moderate to severe CHF [8]. 6 weeks passive electrical stimulation reduced the risk of heart failure-related hospitalizations [9], and in active exercise, intermittent exercise elicits superior improvements in peak VO2 and VE/VCO2 slope compared to continuous exercise in HF patients [10]. Furthermore, the use of web-based and mobile applications, phone interviews, and various wearable activity-tracking devices provides opportunities to regularly engage CR patients in secondary prevention at home. It also has the potential to substantially increase accessibility, reduce costs, and improve prognosis [11]. However, studies on early CR in patients who developed CHF soon after AMI following PCI are scarce. A pilot study done by Houchen L et al. indicated that early CR could significantly reduce depression, enhance exercise tolerance and decrease CHF-associated hospital admission [12]. Unfortunately, the study population was small and no control group was presented for comparison. In view of this, this study evaluated the effects of CR on patients with CHF after AMI following PCI, and compared biochemical parameters and cardio-respiratory fitness (CRF), as well as long-term prognosis at 4 years follow-up.

Methods
Patient population
From June 2016 to May 2017, AMI patients with CHF following PCI were identified in the Department of Cardiology at the First Hospital of Jilin University. The retrospective study protocol was approved by Medical ethics committee of the first hospital of Jilin University.

AMI patients’ ultrasound cardiogram were performed after hemodynamic stabilization 24 h after PCI. The inclusion criteria was in accordance with the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [13]. The exclusion criteria was that exercise prescription could not be performed, including multiple organ failure, history of stroke, ankylosing spondylitis, etc. (Table 1). Patients’ baseline characteristics and biochemical parameters were collected from medical records during the hospitalization by nurse team. Patients were divided into heart failure with reduced ejection fraction (HFrEF) group (left ventricular ejection fraction, LVEF < 40%) and heart failure with mid-range ejection fraction (HFmrEF) group (left ventricular ejection fraction, LVEF: 40–49%). In each group, patients were further divided into non-CR and CR subgroups depending on whether the patients refuse or accept exercise training. In non-CR subgroup, the patients discharged with generic instructions for maintaining physical activity and correct lifestyle, and were told to use the Borg’s rating to perceived exertion (RPE) to assess subjective perception of effort during exercise. Exercise intensity corresponding to Borg’s RPE range 11–13 (“fairly light” to “somewhat hard”) had been recommended [14]. In CR subgroup, program including patient education and counselling, risk factor intervention and exercise training which was started from 48 h after PCI, and continued for 2 weeks. To ensure safety and improve effect, the CR training was carried out under the supervision of three physical and rehabilitation medicine (PRM) physicians including: 3 supervised regular exercise sessions per week on a bicycle (Resistance System: Electromagnetically braked resistance, Power Requirements: Self-generated, Watt: 250 Watts, Heart Rate Monitor: Wireless and Contact Grips) [15] and 4 supervised electrical stimulation sessions per week on no regular exercise day [16]. The regular exercise session included three 3-min intervals aiming at Borg 11–13 by subjective sensation with 2-min recovery periods of 0 W intensity, and lasted for 20 min including warm-up and cool-down [15]. Electrical stimulation was performed 30 min/day, 4 days per week, using a dual-channel battery-powered stimulator Elpha-II 3000 (DANMETER® A/S, Odense, Denmark). The stimulator delivered a biphasic current of 25 Hz frequency. The electrical current characteristics were set up as following: “on–off” mode stimulus (3 s stimulation, 6 s rest), pulse width 300us, rise and fall time 1 s. The intensity of the stimulation was adjusted to produce a visible muscle contraction, but not too strong to make the patients uncomfortable [16]. Adhesive electrodes were placed on both legs over the upper and lower aspects of gastrocnemius muscles, and over the upper-lateral and lower-medial

| Table 1 The reason of not administering exercise prescriptions for the 21 patients |
|-----------------------------------------------|-----------------|
| Multiple organ failure                        | 2               |
| Uremia                                         | 2               |
| Ankylosing spondylitis                        | 6               |
| History of stroke                             | 5               |
| Diabetic ketosis                              | 1               |
| Diabetic foot                                 | 1               |
| Systemic lupus erythematosus                  | 1               |
| Cancer                                        | 1               |
| After aortic stent implantation               | 1               |
| Left ventricular apical thrombosis            | 1               |
| Total                                         | 21              |
portions of the quadriceps muscles. After the 2 weeks CR, patients were advised to continue individualized exercise at home. Individualized exercise prescription was given based on each patient’s CRF from cardiopulmonary exercise testing (CPX) before discharge. The home exercise program included 3–4 sessions of walk or bicycle per week, in which the target training intensity was set at heart rate corresponding to ventilatory threshold (VT) [17]. Patients who accepted the 2-weeks CR were subsequently reassigned into two subgroups based on the major adverse cardiac events (MACE) including cardiogenic death and rehospitalization, namely the MACE group and the non-MACE group. The parameters of CPX between the two subgroups were compared, and the main CPX variables that may predict the prognosis of patients with CHF were identified.

Quantification of cardio-respiratory fitness
CPX, a widely accepted evaluation tool in both the United States (US) and Europe, was used for the assessment of CRF [18, 19]. The measurement of ventilatory gas exchange was used to predict prognosis of death and re-hospitalization [19–21]. In CR patients, the oxygen consumption (VO₂), carbon dioxide production (VCO₂), minute ventilation (VE), partial pressure of end-tidal carbon dioxide (P₆TCO₂), respiratory exchange ratio (RER) and other key CPX variables were measured with submaximal graded exercise test using cardio-respiratory instrumentation Medisoft (E100000011000001, SN: 130619-05-1470, MS, Belgium) after 2-week CR. The exercise load was determined by a cycle ergometer (Ergoselect 100P, ergoline GmbH, Germany) work rate. The progressive load was 10 watts per minute during the graded exercise test, and the pedaling cadence kept at 55–65 revolutions per minute (RPM) throughout the test. The exercise test was terminated if the patient developed any of the following subjective or objective conditions: abnormal hemodynamic or ECG exercise response, or other causes such as dyspnea, angina or lower extremity muscle fatigue.

Clinical follow-up
All patients had informed consent and registered their personal contact telephone number. Follow-up data was acquired through hospital records and telephone interviews which were conducted every 3 months from discharge until cardiac death or December 2020, whichever came first. MACE including cardiac death and re-hospitalization were documented. Patients with cardiac death who lost telephone interviews were identified from the population registry bureau. The average duration of follow-up was 4 years.

Statistical analysis
Continuous variables were presented as means ± standard deviation, and non-normally distributed variables were presented as medians (interquartile range). Categorical variables were expressed as numbers and percentages. Variable parameters between the groups were compared with means of one-way analysis of variance, or Mann–Whitney U test for continuous variables and chi-square test for dichotomous variables, as appropriate. In all analyses, a two-tailed P < 0.05 was considered as statistical significance.

Results
A total of 274 AMI patients with CHF following PCI were identified, 21 patients who were lost to follow-up and 21 patients who were not able to participate cardiopulmonary exercise testing (CPX) were excluded (Table 1, Fig. 1). 232 patients were included in the final analyses, 54 patients had HFrEF (n = 22 in CR and n = 32 in non-CR group) and 178 had HFrmEF (n = 56 in CR and n = 122 in non-CR group). In both HFrEF and HFrmEF groups, there were no significant differences at baseline characteristics between CR and non-CR groups (Tables 2, 3).

Incidence of major cardiovascular events
In the HFrEF group, non-CR patients had higher MACE rate (59.4% vs. 18.2%, P = 0.005) due to higher incidence of cardiac death (31.3% vs. 0.00%, P = 0.002) compared to CR patients (Table 2, Fig. 2). In the HFrmEF group, non-CR patients had higher MACE rate (29.5% vs. 3.6%, P < 0.001) due to higher incidence of heart failure (HF) re-hospitalization (22.1% vs. 3.6%, P = 0.008) compared to CR patients (Table 3, Fig. 3).

The main CPX variables for prognosis prediction
The 78 patients who accepted the 2-weeks CR were subsequently reassigned into two subgroups based on the MACE, namely the MACE group (n = 6) and the non-MACE group (n = 72) (Table 4). Compared with non-MACE group, more patients in MACE group were diabetic (66.7% vs. 22.2%, P = 0.035), had higher serum potassium (4.31 mmol/l vs. 3.96 mmol/l, P = 0.043),
and lower $P_{ET\text{CO}_2}$ at VT (32 mmHg vs. 33 mmHg, $P = 0.016$) (Table 4).

$P_{ET\text{CO}_2}$ at VT was an independent risk factor for re-hospitalization (OR = 0.635, 95% CI: 0.463–0.871, $P = 0.005$), but not serum potassium (OR = 1.239, 95% CI: 0.246–6.249, $P = 0.795$) and history of diabetes (OR = 5.871, 95% CI: 0.778–44.282, $P = 0.086$) (Table 5). $P_{ET\text{CO}_2}$ at VT was found to have predictive value for re-hospitalization after adjusted to sex, age, history of diabetes, blood potassium, ejection fraction (Table 6). The area under the curve was 0.789 and the cut-off point was 33.5 mmHg (Fig. 4). The incidence of re-hospitalization was significantly lower when the $P_{ET\text{CO}_2}$ at VT was higher than 33.5 mmHg (0(0.00% vs. 6(13.64%), $P = 0.03$) (Fig. 5).

**Discussion**

The present study is the first retrospective study evaluating the effects of early CR of passive and active exercise combination in patients with heart failure after AMI following PCI. Our study demonstrated that two-week early CR is able to reduce cardiogenic death in patients with HFrEF, and reduce the rate of re-hospitalization in patients with HFmrEF after AMI. Our data also showed that $P_{ET\text{CO}_2}$ at VT is an independent risk factor for re-hospitalization.

It has been shown that, in patients with HF, exercise-based CR could improve QoL, decrease all-cause hospital admissions and HF-dependent hospital admissions in the short term and potentially reduce mortality in the long term when compared to no exercise patients [22, 23]. Our study expands the previous research by showing that early rehabilitation program involving supervised regular exercise and electrical stimulation can reduce the incidence of cardiac death in patients with HFrEF, and heart failure re-hospitalization in patients with HFmrEF. It is possibly due to: (1) the enhancement of lower limb muscle endurance improved the exercise intolerance of the patients, and it made the patients interested in exercise rehabilitation and enhanced their confidence; (2) individualized exercise prescription was made for CR patients according to VT level by CPX before discharge, so the patients know the safe and effective exercise intensity and duration at home. (3) The PRM specialists recorded the CR results and progress of each patient, and were responsible for the efficiency and safety of CR programs.
[24]. Taken together, early rehabilitation can provide physical fitness reserve and mental self-confidence for the continuous implementation of long-term exercise rehabilitation at home. In consistent with our study, recent research found that early hospital practice guidance, tailored physical activity intervention and follow-up (1, 2, 3, and 4 months after hospital discharge) at home can effectively improve physical performance, QoL, and frailty status in elderly acute coronary syndrome patients [25, 26]. Furthermore, the latest study shows that worsening of perfusion defect size and remodeling are associated to higher risk of events at long-term follow-up in patients

| Table 2 | Comparison of baseline data and MACE (4 years) between the CR patients and NCR patients with HFrEF |
|-----------------|-----------------|-----------------|-----------------|
|                  | HFrEF group (n = 54) | CR (n = 22) | NCR (n = 32) | P     |
| Sex, male (%)   | 17 (77.3%)       | 25 (78.1%) | 0.997        |
| Age (years)     | 57.09 ± 9.17     | 57.03 ± 6.70 | 0.406       |
| History of hypertension, n (%) | 13 (59.1%) | 14 (43.8%) | 0.560       |
| History of diabetes, n (%) | 6 (27.3%) | 12 (37.5%) | 0.590       |
| Smoking history, n (%) | 12 (54.5%) | 14 (43.8%) | 0.580       |
| WBC (10^9/l), median (IQR) | 9.13 ± 3.22 | 10.53 ± 3.65 | 0.143       |
| Platelet (10^9/l), median (IQR) | 217.45 ± 67.00 | 201.91 ± 71.71 | 0.420       |
| HGB (g/l)       | 139 ± 22.31      | 135.09 ± 18.09 | 0.500       |
| Blood potassium (mmol/l) | 4.06 ± 0.40 | 3.99 ± 0.32 | 0.524       |
| Urea nitrogen (mmol/l), median (IQR) | 6.19 ± 1.57 | 5.76 ± 2.34 | 0.422       |
| Creatinine (umol/l), median (IQR) | 76.70 (64.25,92.85) | 77.40 (63.33,95.83) | 0.986 |
| AST (U/l), median (IQR) | 108.30 (22.05, 353.72) | 113.00 (26.48, 380.45) | 0.418 |
| ALT (U/l), median (IQR) | 44.05 (25.33, 76.45) | 51.10 (20.00, 87.07) | 0.758 |
| HDLC (mmol/l)   | 1.09 ± 0.23      | 1.09 ± 0.19   | 0.155       |
| non-HDL-C (mmol/l) | 3.58 ± 0.95     | 3.53 ± 1.24   | 0.869       |
| TC (mmol/l), median (IQR) | 1.46 (1.07, 2.03) | 1.31 (0.96, 2.20) | 0.647       |
| FBS (mmol/l), median (IQR) | 6.14 (5.51, 7.39) | 7.08 (5.82, 11.31) | 0.078 |
| EDLV (mm)       | 58.77 ± 5.15     | 56.84 ± 4.27  | 0.156       |
| EF (%), median (IQR) | 34 (31, 37) | 34.5 (30, 38) | 0.965       |

**Target lesion location**

|                    | CR (n = 22) | NCR (n = 32) | P     |
|--------------------|-------------|--------------|-------|
| LAD, n (%)         | 10 (45.5%)  | 17 (53.1%)   | 0.782 |
| LCX, n (%)         | 2 (9.1%)    | 2 (6.3%)     | 1.000 |
| RCA, n (%)         | 10 (45.5%)  | 13 (40.6%)   | 0.784 |

**KILLIP class**

|       | CR (n = 22) | NCR (n = 32) | P     |
|-------|-------------|--------------|-------|
| 1, n (%) | 0 (0.0%)    | 0 (0.0%)    | –     |
| 2, n (%) | 7 (31.8%)   | 11 (34.4%)  | 1.000 |
| 3, n (%) | 12 (54.5%)  | 10 (31.3%)  | 0.101 |
| 4, n (%) | 3 (13.6%)   | 11 (34.4%)  | 0.119 |

**MACE, n (%)**

|                  | CR (n = 22) | NCR (n = 32) | P     |
|-----------------|-------------|--------------|-------|
| Cardiogenic death, n (%) | 0 (0.0%)**  | 19 (59.4%)   | 0.005 |
| Rehospitalization, n (%) | 4 (18.2%)   | 10 (31.3%)   | 0.003 |
| Myocardial infarction, n (%) | 1 (4.5%)    | 6 (18.8%)    | 0.220 |
| Heart failure, n (%) | 3 (13.6%)   | 3 (9.4%)    | 0.678 |
| Stroke, n (%)    | 0 (0.0%)    | 0 (0.0%)    | –     |

HFrEF: Heart failure with reduced ejection fraction, HFmrEF: Heart failure with mid-range ejection fraction, CR: Cardiac rehabilitation, NCR: Non cardiac rehabilitation, WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non-HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, MACE: major cardiac events, IQR: Interquartile range

Bold: P < 0.05 was considered as statistical significance

*P < 0.05 versus the NCR group

**P < 0.01 versus the NCR group
treated with primary PCI after AMI [27]. Giallauria F etc. confirmed the favourable effects of early exercise-based CR on left ventricular remodeling [28] and myocardial perfusion [29, 30]. The improvement in left ventricular diastolic filling and post-infarction stress-induced myocardial ischaemia in early CR patients may constitute the main pathophysiological basis of reverse left ventricular remodeling [28–30]. Since a dilated left atrium is associated with a number of MACE after AMI, it provides important evidence to encourage the AMI patients in early CR programs, aiming at reducing the risk associated to unfavourable left atrium [31]. These suggest that

Table 3 Comparison of baseline data and MACE (4 years) between the CR patients and NCR patients with HFmrEF

|                          | HFmrEF group (n = 178) |                  |                  |
|--------------------------|------------------------|------------------|------------------|
|                          | CR (n = 56)            | NCR (n = 122)    | P                |
| Sex, male (%)            | 36 (64.3%)             | 95 (77.7%)       | 0.068            |
| Age (years)              | 58.84 ± 10.37          | 61.20 ± 11.31    | 0.174            |
| History of hypertension, n (%) | 29 (51.8%)          | 60 (49.2%)       | 0.872            |
| History of diabetes, n (%) | 14 (25%)              | 36 (29.5%)       | 0.593            |
| Smoking history, n (%)   | 28 (50%)               | 75 (61.5%)       | 0.191            |
| WBC (10^3/l), median (IQR) | 9.88 (7.70, 12.89)    | 9.78 (7.80, 12.40) | 0.802          |
| Platelet (10^3/l), median (IQR) | 228.5 (186, 271.75) | 215.5 (180.5, 245.25) | 0.120      |
| HGB (g/l)                | 141.68 ± 17.316        | 141.91 ± 17.811  | 0.935            |
| Blood potassium (mmol/l) | 3.92 (3.66,4.14)       | 4.04 (3.77, 4.28) | 0.112            |
| Urea nitrogen (mmol/l), median (IQR) | 5.27 (4.20,6.27)     | 5.57 (4.79, 6.77) | 0.170            |
| Creatinine (umol/l), median (IQR) | 63.80 (56.53,82.80)  | 70.85 (57.88, 81.70) | 0.482      |
| AST (U/l), median (IQR)  | 71.65 (34.43, 198.98)  | 94.60 (43.55, 217.80) | 0.156      |
| ALT (U/l), median (IQR)  | 45.15 (24.20, 67.63)   | 44.70 (27.70, 68.47) | 0.590      |
| HDL-C (mmol/l)           | 1.19 (1.00, 1.38)      | 1.21 (1.00, 1.52) | 0.314            |
| non-HDL-C (mmol/l)       | 3.60 ± 0.93            | 3.45 ± 1.05      | 0.341            |
| TC (mmol/l), median (IQR) | 1.33 (1.00, 2.02)     | 1.39 (0.98, 2.04) | 0.961            |
| FBS (mm/l), median (IQR) | 6.60 (4.93, 8.37)      | 6.62 (5.42, 9.73) | 0.238            |
| EDLV (mm)                | 52.04 ± 5.30           | 51.07 ± 5.02     | 0.256            |
| EF (%), median (IQR)     | 46 (42, 48)            | 46 (44, 49)      | 0.057            |
| Target lesion location   |                        |                  |                  |
| LAD, n (%)               | 41 (73.2%)             | 86 (70.5%)       | 0.858            |
| LCX, n (%)               | 2 (3.6%)               | 6 (4.9%)         | 1.000            |
| RCA, n (%)               | 13 (23.2%)             | 30 (24.6%)       | 1.000            |
| KILLIP class             |                        |                  |                  |
| I, n (%)                 | 0 (0.0%)               | 0 (0.0%)         | –                |
| II, n (%)                | 31 (55.4%)             | 73 (59.8%)       | 0.625            |
| III, n (%)               | 13 (23.2%)             | 24 (19.7%)       | 0.691            |
| IV, n (%)                | 12 (21.4%)             | 25 (20.5%)       | 1.000            |
| MACE, n (%)              | 2 (3.6%)**             | 36 (29.5%)       | <0.001           |
| Cardiogenic death, n (%) | 0 (0.0%)               | 9 (7.4%)         | 0.059            |
| Rehospitalization, n (%) | 2 (3.6%)**             | 27 (22.1%)       | 0.002            |
| Myocardial infarction, n (%) | 1 (1.8%)             | 7 (5.7%)         | 0.438            |
| Heart failure, n (%)     | 1 (1.8%)**             | 18 (14.8%)       | 0.008            |
| Stroke, n (%)            | 0 (0.0%)               | 2 (16.4%)        | 1.000            |

HF: Heart failure with reduced ejection fraction, HFrEF: Heart failure with mid-range ejection fraction, CR: Cardiac rehabilitation, NCR: Non cardiac rehabilitation, WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non-HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, MACE: major cardiac events, IQR: Interquartile range

Bold: P < 0.05 was considered as statistical significance
*P<0.05 versus the NCR group
**P<0.01 versus the NCR group
early CR plays an important role in helping patients to make home-based tailored exercise a habit and achieve the improvement in cardiac remodeling and myocardial perfusion. This can help to overcome the main limitations of typical outpatient CR, such as the high number of sessions, high cost, low compliance and lack of long-term maintenance of an active lifestyle.

Exercise intolerance is a major feature of CHF and is associated with reduced functional capacity and poor prognosis. In addition to reduced cardiac function, other causes such as reduced pulmonary reserve, impaired skeletal muscle function significantly contribute to the syndrome in CHF patients respectively, and have becoming the dominant mechanisms of exercise intolerance [32]. Exercise can provide numerous benefits for CHF patients including decreased long-term morbidity and mortality [33], improved cardiac remodeling [34], increased neurovascular functional competency [35], reduced re-hospitalization and improved of cardiorespiratory capacity and QoL [1, 36]. Because the intermittent exercise elicits superior improvements in peak VO₂ and VE/VCO₂ slope compared to continuous exercise training in HF patients [10], the regular exercise session of the study adopted intermittent exercise. Furthermore, the modified group-based high-intensity aerobic interval training intervention over a 12-week period, for a total of 24 training sessions, was found to be more beneficial and more effective compared to the moderate-intensity continuous training in clinically stable (>3 months) HFrEF patients prior to participation [37]. Inspiratory muscle training offers an alternative to exercise training in the most severe HF patients who are unable to exercise, and improves CRF and QoL to a similar as conventional exercise training [38]. The 6-week electrical stimulation training reduced the risk of heart failure-related hospitalizations in HF patients [9]. The benefits of electrical stimulation include improving blood supply and muscle strength, as well as exercise tolerance in severe CHF patients [39, 40], therefore, it can be used as the preferred modality in those unable to actively exercise [8]. In a word, PRM physicians can efficiently apply the electrical stimulation or inspiratory muscle training in early CR, then transition to intermittent exercise training, and the high-intensity aerobic interval training protocol in clinically stable CHF patients. In our study, the re-hospitalization in patients who accepted the 2-week CR after PCI associated to low PEF CO₂, high Serum potassium level and history of diabetes. This may be due to the protective effects of exercise on renal function and the improvement of glycolipid metabolism. Our previous research suggested that up-regulation of nitric oxide synthases in the kidney and left ventricle may contribute, at least in part, to the renal and cardiac protective effects of exercise training in cardiorenal syndrome in chronic heart failure rats [41]. Furthermore, exercise reduces the risk of early diabetic nephropathy by upregulating nitric oxide synthases as well as ameliorating NADPH oxidase and
## Table 4 Comparison of baseline data in patients with cardiac rehabilitation

|                                         | Non-MACE (n = 72) | MACE (n = 6) | P  |
|-----------------------------------------|-------------------|--------------|----|
| Sex, male (%)                           | 49 (68.1%)        | 4 (66.7%)    | 1.00 |
| Age (years)                             | 58.93 ± 9.52      | 52.33 ± 6.95 | 0.103 |
| History of hypertension, n (%)          | 39 (54.2%)        | 3 (50.0%)    | 1.00 |
| History of diabetes, n (%)              | 16 (22.2%)*       | 4 (66.7%)    | 0.035 |
| Smoking history, n (%)                  | 40 (55.6%)        | 4 (66.7%)    | 0.691 |
| History of stroke, n (%)                | 3 (4.2%)          | 0 (0.0%)     | 1.00 |
| WBC (10^9/l), median (IQR)              | 9.55 (7.55, 12.35)| 7.28 (5.34, 11.55) | 0.195 |
| Platelet (10^9/l)                       | 230.4 ± 64.39     | 240.33 ± 73.55 | 0.721 |
| HGB (g/l)                               | 140.77 ± 18.53    | 134.00 ± 21.68 | 0.400 |
| Blood potassium (mmol/l), median (IQR)  | 3.96 (3.66, 4.17)* | 4.13 (3.96, 4.63) | 0.043 |
| Urea nitrogen (mmol/l)                  | 5.70 ± 1.57       | 5.30 ± 1.11  | 0.546 |
| Creatinine (umol/l), median (IQR)       | 71.05 (57.90, 88.80)| 73.80 (62.03, 129.95) | 0.579 |
| AST (U/l), median (IQR)                 | 70.35 (29.43, 203.52)| 70.50 (33.60, 167.83) | 0.751 |
| ALT (U/l), median (IQR)                 | 41.40 (23.30, 65.30)| 66.25 (35.38, 102.98) | 0.111 |
| HDL-C (mmol/l)                          | 1.17 ± 0.25       | 0.99 ± 0.18  | 0.106 |
| Non-HDL-C (mmol/l), median (IQR)        | 3.48 (3.01, 4.18)| 3.51 (3.01, 4.39) | 1.000 |
| TC (mmol/l), median (IQR)               | 1.40 (1.08, 2.00)| 1.67 (1.05, 3.63) | 0.559 |
| FBS (mmol/l), median (IQR)              | 6.47 (5.16, 8.25)| 6.20 (5.26, 7.77) | 0.882 |
| EDLV (mm)                               | 53.66 ± 6.22      | 55.33 ± 5.28 | 0.526 |
| EF (%), median (IQR)                    | 42 (39, 46)       | 38.5 (31, 46.0) | 0.179 |
| Killip class                            |                   |              |     |
| I, n (%)                                | 0 (0.0%)          | 0 (0.0%)     | –   |
| II, n (%)                               | 34 (47.2%)        | 4 (66.7%)    | 0.425 |
| III, n (%)                              | 23 (31.9%)        | 2 (33.3%)    | 1.000 |
| IV, n (%)                               | 15 (20.8%)        | 0 (0.0%)     | 0.590 |
| Target lesion location                  |                   |              |     |
| LAD, n (%)                              | 49 (68.1%)        | 2 (33.3%)    | 0.174 |
| LCX, n (%)                              | 3 (4.2%)          | 1 (16.7%)    | 0.279 |
| RCA, n (%)                              | 20 (27.8%)        | 3 (50.0%)    | 0.353 |
| Rehospitalization, n (%)                | 0 (0.0%)**        | 6 (100.0%)   | <0.001 |
| Myocardial infarction, n (%)            | 0 (0.0%)**        | 2 (33.3%)    | 0.005 |
| Heart failure, n (%)                    | 0 (0.0%)**        | 4 (66.7%)    | <0.001 |
| Stroke, n (%)                           | 0 (0.0%)          | 0 (0.0%)     | –   |
| R-HR (bpm), median (IQR)                | 72 (67, 81)       | 79 (56, 90.5) | 0.751 |
| E-HR(bpm), median (IQR)                 | 95 (87, 109)      | 105.3 (89.75, 118.25) | 0.317 |
| E-VE (l/min), median (IQR)              | 28.95 (25.45, 34.00)| 30.95 (22.88, 35.42) | 0.913 |
| △VE (l/min), median (IQR)               | 16.80 (13.73, 21.20)| 15.20 (10.93, 21.88) | 0.586 |
| VE/MVV (%), median (IQR)                | 28 (25.25, 31.75)| 29.5 (20.5, 36.25) | 0.992 |
| VO2 at VT (ml/kg/min), median (IQR)     | 9 (10, 11)        | 9 (7.5, 11)  | 0.135 |
| E-VCO2 (l/min), median (IQR)            | 0.70 (0.61, 0.85)| 0.64 (0.47, 0.82) | 0.383 |
| △CO2 (l/min), median (IQR)              | 0.49 (0.38, 0.57)| 0.39 (0.25, 0.56) | 0.175 |
| VE/VCO2 slope, median (IQR)             | 35.10 (32.53, 38.89)| 36.34 (35.98, 42.86) | 0.181 |
| R-PETCO2 (mmHg), median (IQR)           | 29 (28, 30)       | 28 (26.25, 30.25) | 0.254 |
| P2CO2 at VT (mmHg), median (IQR)        | 33 (32, 34)*      | 32 (29, 33)  | 0.016 |
| △P2CO2 (mmHg), median (IQR)            | 4 (3, 5)          | 3 (1.25, 4.25) | 0.107 |

WBC: White blood cell, HGB: Hemoglobin, AST: Glutamic pyruvic transaminase, ALT: Glutamic pyruvic aminotransferase, HDL-C: High density lipoprotein cholesterol, non-HDL-C: non-High density lipoprotein cholesterol, TC: total cholesterol, FBS: Fasting blood sugar, EDLV: End diastolic diameter of left ventricle, EF: Ejection fraction, HFrEF: Heart failure with reduced ejection fraction, LM: The left main coronary artery, LAD: Left anterior descending branch, LCX: Left circumflex branch, RCA: Right coronary artery, R-HR: Rest heart rate, E-HR: Exercise Heart Rate, E-VE: Exercise Minute ventilation, △VE: Margin of Minute ventilation, VE/MVV%: The ratio of minute ventilation to the maximum expected value, VO2 at VT: Oxygen consumption per kilogram of weight per minute at anaerobic threshold, E-VCO2: Exercise Carbon dioxide production, △VCO2: Margin of Minute ventilation Carbon dioxide production, VE/VCO2 slope: Minute ventilation/Carbon dioxide production, R-PETCO2: Rest
α-oxoaldehydes in the kidney of zucker diabetic fatty (ZDF) rats [42].

CRF is now being considered as an essential marker and should be assessed in health screenings [43]. It is widely used in diagnosis, functional evaluation and prognosis prediction in clinic. CPX is the most precise tool to determine exercise tolerance and considered as the reference clinical procedure for assessing CRF by quantifying peak VO₂ an indicator for individuals’ capacity to generate energy for strenuous exercise [43]. The characteristic

Table 4 (continued)
Partial pressure of end-tidal carbon dioxide, $P_{\text{ET}}CO_2$ at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold, $\Delta P_{\text{ET}}CO_2$: Margin of Partial pressure of end-tidal carbon dioxide, MACE: major cardiac events, IQR: Interquartile range

|                        | OR   | 95% CI             | P   |
|------------------------|------|--------------------|-----|
| $P_{\text{ET}}CO_2$ at VT (mmHg) | 0.635 | 0.463–0.871          | 0.005 |
| Blood potassium (mmol/l) | 1.239 | 0.246–6.249          | 0.795 |
| History of diabetes (%) | 5.871 | 0.778–44.282         | 0.086 |

Bold: $P < 0.05$ was considered as statistical significance

Table 5 Analysis of risk factors of MACE in patients with rehabilitation (Cox multivariate regression analysis)

|                        | OR   | 95% CI             | P   |
|------------------------|------|--------------------|-----|
| $P_{\text{ET}}CO_2$ at VT (mmHg) | 0.635 | 0.427–0.944          | 0.025 |
| Blood potassium (mmol/l) | 1.239 | 0.246–6.249          | 0.795 |
| History of diabetes (%) | 5.871 | 0.778–44.282         | 0.086 |

Bold: $P < 0.05$ was considered as statistical significance

Table 6 Crude and multivariable-adjusted odds ratios using the cutoff values of $P_{\text{ET}}CO_2$ at VT for MACE

|                        | OR   | 95% CI             | P   |
|------------------------|------|--------------------|-----|
| $P_{\text{ET}}CO_2$ at VT (mmHg) | 0.635 | 0.427–0.944          | 0.025 |
| Crude                  | 0.612 | 0.405–0.924          | 0.019 |
| Multivariable-adjusted | 0.542 | 0.342–0.860          | 0.009 |

Bold: $P < 0.05$ was considered as statistical significance

Obtained by using Logistic regression

OR odds ratio, CI confidence interval

$P_{\text{ET}}CO_2$ at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold, MACE: major cardiac events

a Adjusted to history of diabetes, blood potassium
b Adjusted to sex, age, history of diabetes, blood potassium, ejection fraction

Fig. 4 The ROC curve of $P_{\text{ET}}CO_2$ at VT. $P_{\text{ET}}CO_2$ at VT: Partial pressure of end-tidal carbon dioxide at anaerobic threshold
of CPX data in patients with CHF are: decreased VO₂ at VT < 40% of the predicted VO₂ max, O₂ pulse < 85% of the age-predicted value and as a plateau, increased VE/VCO₂, wide breathing reserve and usually normal O₂ saturation [44]. For patients under medical treatment, a peak VO₂ < 10.0 ml/kg/min and a VE/VCO₂ slope ≥45 exist at the same time would indicate a very poor prognosis over the following 4-year [17]. In consistent with these data, our results indicate that early CR patients with VE/VCO₂ slope < 36 have a good cardiovascular prognosis. Other studies also reported that VE/VCO₂ slope is an excellent independent value on evaluating the long term prognosis in CHF, even better than peak VO₂ and can be achieved only from sub-maximal exercise [45, 46]. Moreover, heart rate recovery (HRR), defined as the fall in HR during the first minute after exercise, is a marker of vagal tone, which is a powerful predictor of mortality in patients with coronary artery disease [47] and in older patients [48]. Because autonomic dysfunction expressed by post-exercise slower HRR in post-infarction patients, is associated with increased high mobility group box-1 protein, which is a critical mediator of inflammatory processes [49]. The patients after AMI, discharged with a specific home-based exercise training programme and instructions for 3-month, was useful for improving HRR, which was correlated to the improvement in peak VO₂ and VE/VCO₂ slope [47, 48].

Of note, in order to achieve the prediction accuracy of peak VO₂ value on CHF, maximal exercise (at least RER > 1.05) should be achieved during the test [44]. However, it is difficult to achieve a maximal test in most CHF patients due to the exercise intolerance. The six-minute walk test is a reproducible, well tolerated, and widely used tool for measuring the response to various rehabilitation interventions in cardiovascular and pulmonary diseases, and is also a powerful prognostic marker for the severity of cardiac and pulmonary diseases [50]. It corresponds to sub-maximal exercise, being approximately equivalent to the VT in CHF patients [50]. The 2016 EACPR/AHA updated the scientific statement, and felt it is important to note that VO₂ at VT holds broad applicability in the context of assessing the capacity [51]. Furthermore, we also showed that VO₂ at VT < 10.5 ml/kg/min is an independent risk factor for cardiovascular disease prognosis and could be used as an evaluating hallmark for Phase I cardiac rehabilitation in patients.
with acute ST segment elevation myocardial infarction (STEMI) after PCI [52]. The \( P_{\text{ET}} \text{CO}_2 \) both at rest and during exercise have been found to be positively correlated with the prognosis of systolic heart failure [53]. Abnormalities in the \( P_{\text{ET}} \text{CO}_2 \) in patients with HCM have been thought to enhance pulmonary pressures [53].

In the present study, we found that \( P_{\text{ET}} \text{CO}_2 \) at VT is a marker for prediction of re-hospitalization after adjusted to sex, age, history of diabetes, blood potassium and ejection fraction for patients with CHF after AMI. Lower \( P_{\text{ET}} \text{CO}_2 \) is an indicator of less \text{CO}_2 production in the body and/or pulmonary arterial perfusion, or the cardiac output [53]. The sensitivity of respiratory chemo-receptors increases when the sympathetic nerve is activated and/or acidosis occurs in HF patients. While in insufficient expansion and with increased dead space between artery and alveolus, diffusion of \text{CO}_2 is less, hence, \( P_{\text{ET}} \text{CO}_2 \) decreases [53]. The re-hospitalization is associated with exercise intolerance in patients with CHF. This could be attributable to the impaired cardiac reserve, decreased respiratory and reduced peripheral skeletal muscle function, which contribute to the decrease in \( P_{\text{ET}} \text{CO}_2 \) at VT. Therefore, \( P_{\text{ET}} \text{CO}_2 \) at VT is an independent risk factor for re-hospitalization but not high serum potassium and history of diabetes.

The limitations of this study include: (1) the participants in the non-CR group were not assessed for CRF using CPX before discharge so it is not clear which parameters of cardiopulmonary fitness (cardiac outcome or pulmonary reserve or peripheral skeletal muscle function) were improved by early rehabilitation in two weeks. (2) Lack of home exercise data in CR group and non-CR group, so further research is needed to explore the influence of early CR on home-based healthy lifestyle development and the influence of home exercise amount on long-term prognosis. (3) Lack of field test application in CR group and non-CR group, future study will be conducted using six-minute walk test.

In conclusion, early CR decreases the incidence of cardiovascular events in patients with CHF after AMI following PCI. The \( P_{\text{ET}} \text{CO}_2 \) at VT is an independent risk factor for re-hospitalization, and can be used as a key evaluating hallmark for early CR in patients with CHF after AMI.

**Abbreviations**

CHF: Congestive heart failure; PCI: Percutaneous coronary intervention; AMI: Acute myocardial infarction; QoL: Quality of life; CR: Cardiac rehabilitation; CRF: Cardio-respiratory fitness; HFREF: Heart failure with reduced ejection fraction; HFrEmEF: Heart failure with mid-range ejection fraction; RPE: Rating to perceived exertion; PRM: Physical and rehabilitation medicine; MACE: Major adverse cardiac events; CPX: Cardio-pulmonary exercise testing; VT: Ventilatory threshold; VE: Minute ventilation; \( \text{VO}_2 \): Oxygen consumption; \( \text{VCO}_2 \): Carbon dioxide production; HRR: Heart rate recovery; \( P_{\text{ET}} \text{CO}_2 \): Partial pressure of end-tidal carbon dioxide; RER: Respiratory exchange ratio.

**Authors’ contributions**

PC and YZ conceived and designed the study. HC, WZ, WS, XZ, RL, WS, LW and LZ performed the experiments and statistical analysis. HC wrote the paper. PC reviewed and edited the manuscript. All authors read and approved the manuscript.

**Funding**

This assessment is funded by National Key R&D Program of China. No. 2016YFC0900903, National Natural Science Foundation of China: No.81301667, and Science and Technology Development Plan of Jilin Province: No. 202102041199Y. The funding bodies were not involved in the study design, data collection or analysis, or writing of the manuscript.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**

This work was approved by Medical Ethics Committee of The First Hospital of Jilin University (Approval Number: 2016-281). All methods were carried out in accordance with relevant guidelines and regulations, and informed consent was obtained from all participants or, if participants are under 16, from a parent and/or legal guardian. All information used for data analysis in this study was anonymized.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 The Cardiovascular Center, First Hospital of Jilin University, 71 Xinmin Road, Changchun 130021, Jilin, China. 2 National Center for Cardiovascular Disease China, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

**Received:** 19 August 2021  **Accepted:** 26 October 2021  **Published online:** 30 October 2021

**References**

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.

2. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)—executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37(8):215–39.

3. Piña IL, Apstein CS, Balady GJ, et al. Determinants of exercise intolerance in patients with heart failure (ExTraMATCH). BMJ. 2004;328(7433):189.

4. Haykowsky MJ, Tomczak CR, Scott JM, Paterson DI, Kitzman DW. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328(7433):189.

5. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2021;42(34):3227–337.
8. Smart NA, Dieberg G, Giallauria F. Functional electrical stimulation for chronic heart failure: a meta-analysis. Int J Cardiol. 2013;167(1):80–6.
9. Kadoglou NP, Mandila C, Karavidas A, et al. Effect of functional electrical stimulation on cardiovascular outcomes in patients with chronic heart failure. Eur J Prev Cardiol. 2017;24(8):833–9.
10. Smart NA, Dieberg G, Giallauria F. Intermittent versus continuous exercise training in chronic heart failure: a meta-analysis. Int J Cardiol. 2013;166(2):352–8.
11. Lavej CJ, Arena R, Franklin BA. Cardiac rehabilitation and healthy lifestyle interventions: rectifying program deficiencies to improve patient outcomes. J Am Coll Cardiol. 2016;67(1):13–5.
12. Houchen L, Watt A, Boyce S, Singh S. A pilot study to explore the effectiveness of “early” rehabilitation after a hospital admission for chronic heart failure. Physiother Theory Pract. 2012;28(5):355–8.
13. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
14. Scherr J, Wolfram B, Christle JW, Pressler A, Wagenpfeil S, Halle M. Associations between Borg’s rating of perceived exertion and physiological measures of exercise intensity. Eur J Appl Physiol. 2013;113(1):147–55.
15. Stolten A, Connaides V, Halle M, Linke A, Prescott E,Ellingsen Ø. Controlled study of myocardial recovery after interval training in heart failure: SMARTERX-HF-rationale and design. Eur J Prev Cardiol. 2012;19(4):813–21.
16. Harris S, Lehto M, Mackenzie G, Fox KA, Denzer MA. A randomised study of home-based electrical stimulation of the legs and conventional bicycle exercise training for patients with chronic heart failure. Eur Heart J. 2003;24(9):871–8.
17. Guazzi M, Adams V, Connaides V, et al. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126(18):2261–74.
18. Arena R, Myers J, Guazzi M. The future of aerobic exercise testing in clinical practice: is it the ultimate vital sign? Future Cardio. 2010;6(3):325–42.
19. Lauer M, Froelicher ES, Williams M, Kligfield P. Cardiac rehabilitation medicine specialist in contemporary cardiac rehabilitation. JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(7):2209–25.
20. Smart NA, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med. 2004;116(10):693–706.
21. Haykowsky MJ, Liang Y, Pechter D, Jones LW, McAlister FA, Clark AM. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol. 2007;49(24):2392–36.
22. Antunes-Correa LM, Kanamura BY, Melo RC, et al. Exercise training improves neurovascular control and functional capacity in heart failure patients regardless of age. Eur J Prev Cardiol. 2012;19(4):822–9.
23. Davies EJ, Mosham T, Rees K, et al. Exercise training for systolic heart failure: cochrane systematic review and meta-analysis. Eur J Heart Fail. 2010;12(7):706–15.
24. Papathanasiou JV, Petrov I, Tokmakova MP, Dimitrova DD, Spasov L, Dzhafar NS, Tsekoura D, Yianniotis Y, Ferreira AS, Lopes AJ, Rosulescu E, Foti C. Group-based cardiac rehabilitation interventions. A challenge for physical and rehabilitation medicine physicians: a randomized controlled trial. Eur J Phys Rehabil Med. 2020;56(4):479–88.
25. Smart NA, Giallauria F, Dieberg G. Efficacy of inspiratory muscle training in chronic heart failure patients: a systematic review and meta-analysis. Int J Cardiol. 2013;167(4):1502–7.
26. Dobias P, Novakova M, Siegelova J, et al. Low-frequency electrical stimulation increases muscle strength and improves blood supply in patients with chronic heart failure. Circ J. 2006;70(1):75–82.
27. Karavidas A, Parisis JT, Matzaraki V, et al. Functional electrical stimulation is more effective in severe symptomatic heart failure patients and improves their adherence to rehabilitation programs. J Card Fail. 2010;16(3):244–9.
28. Ito D, Ito G, Mori N, et al. Exercise training upregulates nitric oxide synthases in the kidney of rats with chronic heart failure. Clin Exp Pharmacol Physiol. 2013;40(9):617–25.
29. Ito D, Cao P, Kakihana T, et al. Chronic running exercise alleviates early progression of nephropathy with upregulation of nitric oxide synthases and suppression of glycation in Zucker diabetic rats. PLoS ONE. 2015;10(9):e0138037.
30. Kaminsky LA, Arena R, Ellingsen Ø, et al. Cardiorespiratory fitness and cardiovascular disease—the past, present, and future. Prog Cardiovasc Dis. 2019;62(2):86–93.
31. Herdy AH, Ritt LE, Stein R, et al. Cardiopulmonary exercise test: background, applicability and interpretation. Arch Bras Cardiol. 2016;107(5):467–81.
32. Francis DP, Sharrim M, Davies LC, et al. Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO2 slope and peak VO2. Eur Heart J. 2000;21(2):154–61.
33. Corrêa U, Mezzani A, Bosimini E, Scapellato F, Imparato A, Giannuzzi P. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity. Am J Cardiol. 2002;89(3):418–26.
34. Giallauria F, Del Lorenzo A, Pilerci F, Manakos A, Lucci R, Paciolo M, Del Forno D, Vigorito C. Left ventricular remodelling in patients with moderate systolic dysfunction after myocardial infarction: favourable effects of exercise training and predictive role of N-terminal pro-brain natriuretic peptide. Eur J Cardiovasc Prev Rehabil. 2008;15(1):113–8.
rehabilitation on end-exercise heart rate recovery after myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2006;13(4):544–50.

48. Giallauria F, Lucci R, Pietrosante M, Gargiulo G, De Lorenzo A, D’Agostino M, Gerundo G, Abete P, Rengo F, Vigorito C. Exercise-based cardiac rehabilitation in improves heart rate recovery in elderly patients after acute myocardial infarction. J Gerontol A Biol Sci Med Sci. 2006;61(7):713–7.

49. Giallauria F, Cirillo P, Lucci R, Pacileo M, D’Agostino M, Maietta P, Vitelli A, Chiariello M, Vigorito C. Autonomic dysfunction is associated with high mobility group box-1 levels in patients after acute myocardial infarction. Atherosclerosis. 2010;208(1):280–4.

50. Papathanasiou JV, Ilieva E, Marinov B. Six-minute walk test: an effective and necessary tool in modern cardiac rehabilitation. Hellenic J Cardiol. 2013;54(2):126–30.

51. Guazzi M, Arena R, Halle M, Pepoli MF, Myers J, Lavie CJ. Focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2016;133(24):e694-711.

52. Cai H, Zheng Y, Liu Z, et al. Effect of pre-discharge cardiopulmonary fitness on outcomes in patients with ST-elevation myocardial infarction after percutaneous coronary intervention. BMC Cardiovasc Disord. 2019;19(1):210.

53. Cardiopulmonary AH, Test E. Cardiopulmonary exercise test. Int Heart J. 2017;58(S):654–65.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.